Adaptimmune Extends Funding Runway Ahead Of Clinical Results In Second Half

UK T-cell receptor biotech, Adaptimmune, has raised $100m from a direct offering of its ADSs as it prepares for the reporting of clinical response data later this year from early clinical studies in cancer patients.  

Sprouting
• Source: Shutterstock

The next six months will be key for Adaptimmune Therapeutics PLC as it garners initial efficacy data from early clinical studies of its candidate T-cell receptor therapies, reason enough to have financial resources in place to take the company to the next stage of development.

The NASDAQ-quoted biotech, which has facilities in Philadelphia, US, and Oxford, UK, confirmed the importance of its soon-to-be reported clinical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.